Physician profile
Rachel Fields
NPI 1336535715
$2,521.45
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,194 · 2022: $1,283 · 2023: $32.91 · 2024: $11.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $44.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $44.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $823.04 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $336.18 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $256.37 | 2021-2024 | Lifevest |
| Boston Scientific Corporation | $229.17 | 2021-2022 | |
| Biotronik INC. | $113.79 | 2022 | |
| Novartis Pharmaceuticals Corporation | $101.92 | 2021-2022 | |
| Amgen INC. | $86.19 | 2021-2022 | |
| Cardiovascular Systems INC. | $85.33 | 2021 | |
| Janssen Pharmaceuticals, INC | $83.84 | 2021-2022 | |
| Daiichi Sankyo INC. | $79.65 | 2021-2022 | |
| Novo Nordisk INC | $72.20 | 2021-2022 | |
| Amarin Pharma, INC. | $62.45 | 2021-2022 | |
| Esperion Therapeutics, INC. | $49.92 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $43.79 | 2021-2022 | |
| Vifor Pharma, INC. | $36.40 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $30.63 | 2022 | |
| Merck Sharp & Dohme LLC | $30.58 | 2021-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.